In a model recapitulating the loss of CD19 (CD19−/CD22+ tumor), AUTO3 CAR T cells were able to stop tumor growth and reduce tumor burden and had a higher CAR T cell persistence in the bone marrow compared with the FMC63 CAR, which showed no improvement over non-transduced T cells (Fig. 1e and Extended Data Fig. 4). Here, CD22 is linked to neoplasm.